Protein Summary
Integrins alpha-4/beta-1 (VLA-4) and alpha-4/beta-7 are receptors for fibronectin. They recognize one or more domains within the alternatively spliced CS-1 and CS-5 regions of fibronectin. They are also receptors for VCAM1. Integrin alpha-4/beta-1 recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-4/beta-7 is also a receptor for MADCAM1. It recognizes the sequence L-D-T in MADCAM1. On activated endothelial cells integrin VLA-4 triggers homotypic aggregation for most VLA-4-positive leukocyte cell lines. It may also participate in cytolytic T-cell interactions with target cells. ITGA4:ITGB1 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415). ITGA4:ITGB1 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). The gene encodes a member of the integr ...more
- ENST00000339307
- ENSP00000340149
- ENSG00000115232
- ENST00000397033
- ENSP00000380227
- CD49D
- IA4
- CD49D
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
gene perturbation | 0.94 | ||
interacting protein | 0.92 | ||
cellular component | 0.79 | ||
biological term | 0.77 | ||
transcription factor perturbation | 0.74 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 471.21 (req: < 5)
Gene RIFs: 205 (req: <= 3)
Antibodies: 1835 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 471.21 (req: >= 5)
Gene RIFs: 205 (req: > 3)
Antibodies: 1835 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 28
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 128
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 2